Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives
Molecules · 12.04.2025 · 30 (8) · 1731
DOI: 10.3390/molecules30081731 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 12.04.2025. Verfasst von Daoyuan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Insitute of Health, NIH.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid progression, early metastasis, and high recurrence rates. Historically considered a homogeneous disease, recent multi-omic studies have revealed distinct molecular subtypes driven by lineage-defining transcription factors, including ASCL1, NEUROD1, POU2F3, and YAP1, as well as an inflamed subtype (SCLC-I). These subtypes exhibit unique therapeutic vulnerabilities, thereby paving the way for precision medicine and targeted therapies. Despite recent advances in molecular classification, tumor heterogeneity, plasticity, and therapy resistance continue to hinder clinical success in treating SCLC patients. To this end, novel therapeutic strategies are being explored, including BCL2 inhibitors, DLL3-targeting agents, Aurora kinase inhibitors, PARP inhibitors, and epigenetic modulators. Additionally, immune checkpoint inhibitors (ICIs) show promise, particularly in immune-enriched subtypes of SCLC patients. Hence, a deeper understanding of SCLC subtype characteristics, evolution, and the regulatory mechanisms of subtype-specific transcription factors is crucial for rationally optimizing precision therapy. This knowledge not only facilitates the identification of subtype-specific therapeutic targets, but also provides a foundation for overcoming resistance and developing personalized combination treatment strategies. In the future, the integration of multi-omic data, dynamic molecular monitoring, and precision medicine approaches are expected to further advance the clinical translation of SCLC subtype-specific therapies, ultimately improving patient survival and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID-Profile: Daoyuan Huang, David K Simon
Förderung
- NINDS NIH HHS
- National Insitute of Health
- NIH
Zitieren
APA
Huang, D., Wang, J., Chen, L., Jiang, W., Inuzuka, H., Simon, D. K., & Wei, W. (2025). Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives. Molecules, 30(8), 1731. https://doi.org/10.3390/molecules30081731
Vancouver
Huang D, Wang J, Chen L, Jiang W, Inuzuka H, Simon DK, et al. Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives. Molecules. 2025;30(8):1731. doi:10.3390/molecules30081731
BibTeX
@article{Huang2025,
author = {Huang, Daoyuan and Wang, Jingchao and Chen, Li and Jiang, Weiwei and Inuzuka, Hiroyuki and Simon, David K and Wei, Wenyi},
title = {Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives},
journal = {Molecules},
year = {2025},
volume = {30},
number = {8},
pages = {1731},
doi = {10.3390/molecules30081731}
}
EUVIMED